Shares of PRA Health Sciences Inc. (NASDAQ:PRAH) saw an uptick in trading volume on Monday . 505,717 shares traded hands during mid-day trading, an increase of 24% from the previous session’s volume of 406,884 shares.The stock last traded at $47.08 and had previously closed at $46.38.

Several brokerages have recently issued reports on PRAH. KeyCorp restated a “hold” rating on shares of PRA Health Sciences in a report on Sunday, May 22nd. Citigroup Inc. upgraded shares of PRA Health Sciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $51.00 to $53.00 in a report on Wednesday, May 4th. Jefferies Group reiterated a “buy” rating and issued a $57.00 price target on shares of PRA Health Sciences in a report on Friday. Credit Suisse Group AG began coverage on shares of PRA Health Sciences in a report on Monday, June 20th. They issued a “neutral” rating and a $43.00 price target on the stock. Finally, First Analysis began coverage on shares of PRA Health Sciences in a report on Monday, June 20th. They issued an “equal weight” rating and a $47.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $48.61.

The firm has a market cap of $2.87 billion and a PE ratio of 40.38. The company’s 50 day moving average price is $43.19 and its 200 day moving average price is $44.12.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.04. The firm had revenue of $394.20 million for the quarter, compared to analysts’ expectations of $381.25 million. During the same period last year, the company earned $0.47 earnings per share. The firm’s revenue was up 16.0% on a year-over-year basis. On average, equities analysts forecast that PRA Health Sciences Inc. will post $2.44 earnings per share for the current year.

In related news, major shareholder Pra Investors L.P. Kkr sold 4,907,692 shares of the stock in a transaction on Friday, May 6th. The stock was sold at an average price of $46.70, for a total transaction of $229,189,216.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Linda Baddour sold 92,308 shares of the stock in a transaction on Friday, May 6th. The shares were sold at an average price of $46.70, for a total value of $4,310,783.60. The disclosure for this sale can be found here.

Other hedge funds recently added to or reduced their stakes in the company. Cornerstone Capital Management Holdings LLC. bought a new stake in PRA Health Sciences during the fourth quarter valued at $1,346,000. State Board of Administration of Florida Retirement System raised its stake in PRA Health Sciences by 470.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 34,699 shares of the company’s stock valued at $1,571,000 after buying an additional 28,612 shares during the last quarter. California State Teachers Retirement System raised its stake in PRA Health Sciences by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 36,864 shares of the company’s stock valued at $1,669,000 after buying an additional 630 shares during the last quarter. First Trust Advisors LP raised its stake in PRA Health Sciences by 24.8% in the fourth quarter. First Trust Advisors LP now owns 54,199 shares of the company’s stock valued at $2,454,000 after buying an additional 10,780 shares during the last quarter. Finally, Russell Frank Co raised its stake in PRA Health Sciences by 639.9% in the fourth quarter. Russell Frank Co now owns 88,437 shares of the company’s stock valued at $4,176,000 after buying an additional 76,485 shares during the last quarter.

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.